e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

903.02 -7.53 (-0.83%)

Official Closing Price Updated: 7:00 PM EDT, Mar 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

The Vanguard Fund That Can Turn $400 Per Month Into More Than $1.5 Million ↗

March 24, 2026

Even if you're starting with $0 today, you can still build up a million-dollar portfolio with regular monthly investments.

Via The Motley Fool

Topics ETFs Retirement

Want to Buy the Dip on Eli Lilly? Consider This Low-Cost Vanguard ETF ↗

March 24, 2026

After nearly tripling between 2023 and the end of 2025, Lilly is undergoing a steep sell-off in 2026.

Via The Motley Fool

Topics ETFs

Regional Bank Stock Up 33% as $3.7 Million Exit Tells a Different Story ↗

March 24, 2026

First Bancorp delivers banking, lending, and digital financial services across the Carolinas, serving individuals and local businesses.

Via The Motley Fool

Topics Regulatory Compliance

The Great Divergence: Q1 2026 M&A Hits Record $813.3 Billion Amidst "K-Shaped" Recovery

March 24, 2026

As the first quarter of 2026 draws to a close, the global mergers and acquisitions (M&A) market has delivered a paradox that is reshaping the financial landscape. Preliminary data reveals that total...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Eli Lilly To Phase Out Select Insulin Products Across Europe By 2027 ↗

March 24, 2026

Eli Lilly will discontinue select insulin products in EU markets by Q2 2027, citing commercial reasons as regulators monitor supply impact.

Via Benzinga

Think Novo Nordisk Can't Keep Up in the GLP-1 Market? Its Latest Drug Approval Could Be a Game Changer ↗

March 24, 2026

The company recently obtained approval for a higher-dose version of Wegovy.

Via The Motley Fool

Institutional Titans Bet Big on Amgen as Dividend Yield Hits 2.9% Benchmark

March 23, 2026

In a decisive show of confidence for the biotechnology sector, institutional heavyweights have significantly ramped up their positions in Amgen (NASDAQ: AMGN) throughout the first quarter of 2026....

Via MarketMinute

Topics ETFs Earnings

$1000 Invested In Eli Lilly 10 Years Ago Would Be Worth This Much Today ↗

March 23, 2026

Via Benzinga

The Earnings Fortress: S&P 500 Defies 'Permacrisis' with Fifth Consecutive Quarter of Double-Digit Growth

March 23, 2026

As of March 23, 2026, the American corporate engine has proven itself to be remarkably high-revving, even as the global landscape shifts beneath it. Despite a volatile start to the year characterized...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

What's Going On With Eli Lilly On Monday? ↗

March 23, 2026

Global CEOs signal cautious China expansion as Eli Lilly ramps investment, while the Supreme Court revives Actos litigation risks.

Via Benzinga

Goldman Sachs Bullish Forecast: 15% Increase in 2026 U.S. M&A Activity

March 23, 2026

As the first quarter of 2026 comes to a close, the financial world is buzzing with a renewed sense of optimism. Goldman Sachs (NYSE: GS) has released its highly anticipated 2026 Global M&A Outlook,...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Here's How Much Upside Eli Lilly Stock Has, According to Analysts ↗

March 23, 2026

Eli Lilly's stock has been receiving many upgrades after posting strong quarterly results in February.

Via The Motley Fool

The Best Stocks to Invest $1,000 in Right Now ↗

March 23, 2026

Buying $1,000 of each of these stocks should pay off nicely over the long run.

Via The Motley Fool

Topics Artificial Intelligence

1 Healthcare Stock Worth Your Attention and 2 Facing Headwinds

March 23, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...

Via StockStory

Topics Artificial Intelligence

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

March 22, 2026

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl...

Via StockStory

Topics Artificial Intelligence Intellectual Property

VIG vs NOBL: Which Dividend ETF Should You Buy Now? ↗

March 22, 2026

Explore how each ETF’s unique sector focus and fee structure could impact your dividend strategy and long-term portfolio mix.

Via The Motley Fool

Topics ETFs

Got $1,500? Is It Better to Buy Bitcoin, or Viking Therapeutics? ↗

March 22, 2026

One of these assets is catalyst-driven; the other isn't.

Via The Motley Fool

Topics Intellectual Property

Should You Buy Eli Lilly Stock Before April 10? ↗

March 22, 2026

A catalyst for stock performance may be just ahead.

Via The Motley Fool

Is This Stock a Buy on the Dip? ↗

March 21, 2026

This company has a habit of beating the market over long periods.

Via The Motley Fool

This Hims & Hers Move Could Destroy Competitors ↗

March 21, 2026

The Wegovy pill could change Hims & Hers' growth in 2026.

Via The Motley Fool

Buyer’s Remorse: Why the Early-Week Market Rally Collapsed into a Flight for Safety

March 20, 2026

The promise of a mid-March market recovery vanished this week as a short-lived "relief rally" gave way to a wave of "buyer’s remorse," leaving investors scrambling for cover. What began on Monday as a...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

My Top 3 Drug Stocks for March 2026 ↗

March 20, 2026

These companies have impressive track records of navigating the biggest challenges in their industry.

Via The Motley Fool

Topics Intellectual Property

2 Healthcare Stocks to Buy Before They Get Bought Out ↗

March 20, 2026

Abivax and Nektar Therapeutics are clinical-stage biotech companies that would make attractive buyout targets.

Via The Motley Fool

Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals ↗

March 19, 2026

Both have plenty to offer investors, but one has a better outlook.

Via The Motley Fool

Topics Artificial Intelligence

Eli Lilly Says Experimental Diabetes Drug Shows Weight Loss Of 17% ↗

March 19, 2026

Eli Lilly says retatrutide trial results show major weight loss and blood sugar improvements in the diabetes study.

Via Benzinga

Is It Too Late to Buy Eli Lilly? ↗

March 19, 2026

Eli Lilly's GLP-1 drugs are leaders in a new and exciting drug category, but investors already know this fact.

Via The Motley Fool

Topics Intellectual Property

Should You Buy the Vanguard S&P 500 ETF After the Recent Stock Market Sell-Off? History Offers a Crystal-Clear Answer. ↗

March 19, 2026

Volatility in the stock market often leads to great long-term opportunities for investors.

Via The Motley Fool

Topics ETFs Economy Stocks

1 Reason I'm Never Selling Novo Nordisk Stock ↗

March 19, 2026

I am not turned off by the company's recent setbacks.

Via The Motley Fool

Eli Lilly's Experimental Drug Retatrutide Delivers Strong Weight Loss In Late-Stage Trial ↗

March 19, 2026

Patients taking retatrutide, lost 16.8% of their body weight over 40 weeks.

Via Investor's Business Daily

AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown

March 18, 2026

The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based...

Via MarketMinute

Topics ETFs Economy Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy